Skip to content
10-Q

Quarterly Report

Regulus Therapeutics Inc.

0001628280-24-022266

← back to feed
Filed
May 9, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2024 · May 3, 2024 65.47M sh
Short Term Debt Q1 2024 · Mar 31, 2024 $540K
Short Term Debt Q1 2024 · Dec 31, 2023 $1.33M
Short Term Investments Q1 2024 · Mar 31, 2024 $67.97M
Short Term Investments Q1 2024 · Dec 31, 2023 $0
Current Liabilities Q1 2024 · Mar 31, 2024 $5.68M
Current Liabilities Q1 2024 · Dec 31, 2023 $8.51M
Total Liabilities Q1 2024 · Mar 31, 2024 $6.55M
Total Liabilities Q1 2024 · Dec 31, 2023 $9.56M
Current Assets Q1 2024 · Mar 31, 2024 $101.45M
Current Assets Q1 2024 · Dec 31, 2023 $28.18M
Total Assets Q1 2024 · Mar 31, 2024 $114.14M
Total Assets Q1 2024 · Dec 31, 2023 $30.75M
Cash And Equivalents Q1 2024 · Dec 31, 2023 $23.77M
Cash And Equivalents Q1 2024 · Mar 31, 2023 $30.31M
Shares Diluted Q1 2024 · Mar 31, 2023 16.84M sh
Capex Q1 2024 · Mar 31, 2023 $1K
Operating Cash Flow Q1 2024 · Mar 31, 2023 −$8.11M
Stockholders Equity Q1 2024 · Mar 31, 2023 $26.6M
Stockholders Equity Q1 2024 · Dec 31, 2022 $33.29M
Eps Diluted Q1 2024 · Mar 31, 2023 −$0.42
Eps Basic Q1 2024 · Mar 31, 2023 −$0.42
Sga Expense Q1 2024 · Mar 31, 2023 $2.44M
Rd Expense Q1 2024 · Mar 31, 2023 $4.93M
Net Income Q1 2024 · Mar 31, 2023 −$7.14M
Operating Income Q1 2024 · Mar 31, 2023 −$7.37M